CDP-CholinevsEmoxypine (Mexidol)

CDP-Choline is hydrolyzed by nucleotidases and phosphatases into choline and cytidine after oral ingestion. Choline enters the acetylcholine synthesis pathway via choline acetyltransferase. Cytidine is phosphorylated to CTP and converted to uridine monophosphate (UMP), which enters the Kennedy pathway and stimulates the synthesis of phosphatidylcholine via the enzyme CTP:phosphocholine cytidylyltransferase — phosphatidylcholine is a critical component of neuronal cell membranes and synaptic vesicles. This dual mechanism simultaneously boosts neurotransmitter production and repairs membrane damage from oxidative stress or ischemia. CDP-Choline also increases dopamine D2 receptor density in the striatum and enhances dopamine release. It may modulate glutamate excitotoxicity and support mitochondrial function.

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine succinate) has a 3-hydroxypyridine structure similar to vitamin B6 (pyridoxine). It is one of the most potent inhibitors of lipid peroxidation in brain tissue — it scavenges hydroxyl radicals and peroxyl radicals, inhibits Fe2+-induced lipid peroxidation, and may chelate transition metals. It modulates the GABA-benzodiazepine receptor complex (GABA-A), enhancing GABAergic transmission through positive allosteric modulation — possibly at a site distinct from the classical benzodiazepine binding site, explaining the lack of sedation and tolerance. It improves mitochondrial function (Complex I protection, membrane stabilization), stabilizes cell membranes (reducing fluidity changes during oxidative stress), and enhances cerebral microcirculation (possibly via nitric oxide or prostaglandin modulation). The anxiolytic mechanism may involve partial agonism or different subunit selectivity.